This most recent twist during the Lykos Therapeutics saga threatens A serious overhaul of the corporate’s tactic and route, with Musk ally and billionaire investor Antonio Gracias showing to need to consider the corporation back again towards its nonprofit drug improvement roots and a far more Doblinite philosophy.A fast search of quite a few dar